Follow
Peter Senter
Peter Senter
Seagen, Inc
Verified email at seagen.com
Title
Cited by
Cited by
Year
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
SO Doronina, BE Toki, MY Torgov, BA Mendelsohn, CG Cerveny, ...
Nature biotechnology 21 (7), 778-784, 2003
15012003
Arming antibodies: prospects and challenges for immunoconjugates
AM Wu, PD Senter
Nature biotechnology 23 (9), 1137-1146, 2005
14212005
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate
KJ Hamblett, PD Senter, DF Chace, MMC Sun, J Lenox, CG Cerveny, ...
Clinical cancer research 10 (20), 7063-7070, 2004
13342004
cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity
JA Francisco, CG Cerveny, DL Meyer, BJ Mixan, K Klussman, DF Chace, ...
Blood 102 (4), 1458-1465, 2003
11182003
Monomethylvaline compounds capable of conjugation to ligands
SO Doronina, PD Senter, BE Toki
US Patent 7,498,298, 2009
9292009
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
PD Senter, EL Sievers
Nature biotechnology 30 (7), 631-637, 2012
8862012
Antibody-drug conjugates in cancer therapy
EL Sievers, PD Senter
Annual review of medicine 64, 15-29, 2013
8792013
Antibody–drug conjugates: targeted drug delivery for cancer
SC Alley, NM Okeley, PD Senter
Current opinion in chemical biology 14 (4), 529-537, 2010
8272010
Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
PD Senter, MG Saulnier, JP Brown, DE Kerr
US Patent 4,975,278, 1990
6391990
Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity
SO Doronina, BA Mendelsohn, TD Bovee, CG Cerveny, SC Alley, ...
Bioconjugate chemistry 17 (1), 114-124, 2006
6102006
Contribution of linker stability to the activities of anticancer immunoconjugates
SC Alley, DR Benjamin, SC Jeffrey, NM Okeley, DL Meyer, RJ Sanderson, ...
Bioconjugate chemistry 19 (3), 759-765, 2008
5802008
Potent antibody drug conjugates for cancer therapy
PD Senter
Current opinion in chemical biology 13 (3), 235-244, 2009
5332009
Efficient cancer therapy with a nanobody-based conjugate
V Cortez-Retamozo, N Backmann, PD Senter, U Wernery, P De Baetselier, ...
Cancer research 64 (8), 2853-2857, 2004
5292004
Antibody-drug conjugates for cancer therapy
PJ Carter, PD Senter
The Cancer Journal 14 (3), 154-169, 2008
5212008
Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
PD Senter, SO Doronina, BE Toki
US Patent 7,659,241, 2010
4782010
Chemotherapy delivery issues in central nervous system malignancy: a reality check
LL Muldoon, C Soussain, K Jahnke, C Johanson, T Siegal, QR Smith, ...
Journal of clinical oncology 25 (16), 2295-2305, 2007
4702007
Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index
RP Lyon, TD Bovee, SO Doronina, PJ Burke, JH Hunter, HD Neff-LaFord, ...
Nature biotechnology 33 (7), 733-735, 2015
4692015
Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates
RP Lyon, JR Setter, TD Bovee, SO Doronina, JH Hunter, ME Anderson, ...
Nature biotechnology 32 (10), 1059-1062, 2014
4552014
Reduction− alkylation strategies for the modification of specific monoclonal antibody disulfides
MMC Sun, KS Beam, CG Cerveny, KJ Hamblett, RS Blackmore, ...
Bioconjugate chemistry 16 (5), 1282-1290, 2005
4532005
Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate
NM Okeley, JB Miyamoto, X Zhang, RJ Sanderson, DR Benjamin, ...
Clinical Cancer Research 16 (3), 888-897, 2010
4282010
The system can't perform the operation now. Try again later.
Articles 1–20